Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

ChineseInvestors.com, Inc. (CIIX) Aiming to Help Tackle Epilepsy with a CBD Oil-Based Pharmaceutical

ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China. CBD, also known as cannabidiol, is one […]

CytoDyn Inc. (CYDY) is Tackling HIV Differently

Nestled on the north bank of the Columbia River in the State of Washington is the city of Vancouver, home to CytoDyn Inc. (OTCQB: CYDY). A publicly-held biotech company, CytoDyn manages its efforts to improve the lives of men and women with the human immunodeficiency virus (HIV), focusing its attention on developing new therapies that […]

Net Element, Inc. (NASDAQ: NETE) Giving Clients a 360-Degree View of their Business with Unified Payments Insights

Although the use of big data has been around for years, businesses still do not use it to their full advantage. Despite past reports (http://nnw.fm/Cw1XS) predicting big data to be a key basis for competition, productivity growth, innovation, and consumer surplus, an article by the Harvard Business Review (http://nnw.fm/dY2E4) showcases the fact that most industries […]

RegeneRX Biopharmaceuticals, Inc. (RGRX) Helping Patients with Multiple Sclerosis

Multiple Sclerosis, or MS, is a disease that damages the sheaths of nerve cells in the spinal cord and brain. This progressive disease causes symptoms such as severe fatigue, numbness, blurry vision, and impairment to muscular coordination and speech. According to statistics noted in Healthline (http://dtn.fm/uF91G), multiple sclerosis is now the most widespread disabling neurological […]

Moxian, Inc. (NASDAQ: MOXC) Using Social Media as a Channel to Initiate Online Purchases for Merchants

According to statistics published at ChinaDaily.com (http://nnw.fm/x8NcC), online sales in China have boomed, growing 26.2% year-on-year to reach over five trillion yuan ($751.7 billion) in 2016. With this in mind, researchers and specialists worldwide are looking at China to learn how to initiate more online purchases, but it is not just China’s developed e-commerce market […]

Marinus (NASDAQ: MRNS) Names Michael R. Dougherty to Board, Prepares to Initiate Phase 2 Studies of Ganaxolone

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), on February 1, 2017, named Michael R. Dougherty to its board. A biopharmaceutical company, Marinus is preparing to initiate phase 2 studies of ganaxolone, a drug which treats seizures and anxiety in patients suffering from epilepsy and neuropsychiatric disorders. Dougherty has more than 30 years of experience in the biopharmaceutical […]

 

From Our Blog

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

February 12, 2026

HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity […]

Rotate your device 90° to view site.